Stadol ®

Stadol ® is a partial narcotic analgesic for moderate to severe pain management.

• Stadol ® is the trade name for generic Butorphanol.
• Indications as an opioid analgesic to manage from moderate to severe pain in postoperative conditions, as IV or IM injection.
• Available as an injection solution and nasal spray.
• Stadol ® (or, Butorphanol) is a synthetic derived narcotic analgesic.
• An opioid agonist-antagonist analgesic of the phenanthrene family.
• Stadol’s form is a white crystalline substance, expressed as butorphanol tartrate salt.
• Stadol ® is a mixed morphine-like, agonist-antagonist with low activity at opioid receptors.
• Stadol’s effects on the central nervous system include: depression of sudden respiratory activity or cough, stimulation of the vomit reflex, pinpoint pupils, and sedation.
• Affects the cardiovascular, bronchial, and gastrointestinal systems, influencing motor and bladder activity.
• Stadol ® may produce unpleasant effects such as psychosis, delusions, or hallucinations.
• Respiratory depression produced can be reversed by treatment with Naloxone.
• Pain relief can begin within 15 minutes for intramuscular injection and for the nasal spray.
• Maximum effects may peak within 30 to 60 minutes after injection, and within 1 to 2 hours after nasal administration.
• Duration of the desired effect generally lasts 3 to 4 hours.
• Stadol ® demonstrates antitussive effects.
• Stadol ® is widely metabolized in the liver.
• Elderly patients may experience varied or increased effects.
• Stadol ® is used in postoperative pain management, migraine headache, and preanesthetic medication.
• Caution advisory for use in patients with renal or hepatic impairment, during late labor, and in geriatric patients.
• Stadol is not indicated for pain in early labor, less than 4 hours away or just before childbirth, and may cause breathing complications in a newborn.
• Can also be transmitted in mother’s milk when nursing.
• Stadol ® may not potentiate intraoperative analgesic action in all patient situations.
• Contraindicated in patients hypersensitive to benzethonium chloride, the preservative ingredient in Stadol.
• May precipitate withdrawal symptoms such as anxiety, agitation, diarrhea, dysphoria, hallucinations, mood changes, and weakness in opiate-tolerant patients.
• Associated with episodes of medication abuse.
• Stadol ® may trigger low blood pressure, leading to fainting within the first hour of administration in patients with opiate history.
• Must be taken under the doctor's orders, following instructions since Stadol can be habit forming.
• Use with sedatives or alcoholic beverages increases risk of adverse side effects, dizziness, impaired alertness, and unconsciousness.
• Increased dosage or chronic use, more than prescribed, can lead to opiate dependency.
• Stadol ® Injection and Stadol NS Nasal Spray meet the definition of a Schedule IV narcotic under the Controlled Substances Act (CSA).
• Classified for its potential to cause moderate physical or psychological dependence when abused.
• Of the 6.4 million Americans who misuse prescription medication, more than 73% misused prescription pain relievers (2006, National Household Survey).
  

More about the medication Stadol ® and the Waismann Method of Rapid Detoxification.